Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 987-992

  Balduzzi, A ^a   Lucchini, G ^a   Hirsch, H H ^b,c   Basso, S ^d   Cioni, M ^d   Rovelli, A ^a   Zincone, A ^e   Grimaldi, M ^e   Corti, P ^a   Bonanomi, S ^a   Biondi, A ^a   Locatelli, F ^d,f   Biagi, E ^a   Comoli, P ^d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF PAVIA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

adoptive Immunotherapy; allogeneic transplantation; CTL; GVHD; polyomavirus JC; progressive multifocal leukoencephalopathy

Indexed keywords

ANTIVIRUS AGENT; BUDESONIDE; CIDOFOVIR; CITALOPRAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN VP1; RITUXIMAB; STEROID; T LYMPHOCYTE ANTIGEN; VIRUS ANTIGEN; VIRUS DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGNOSIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMNESIA; ANTIGEN SPECIFICITY; ANTIVIRAL THERAPY; APRAXIA; ARTICLE; ATAXIC APHASIA; BRAIN ATROPHY; BRAIN RADIOGRAPHY; CASE REPORT; CD4 CD8 RATIO; CEREBROSPINAL FLUID ANALYSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; GRAFT RECIPIENT; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LIMB TREMOR; LIMB WEAKNESS; LOW DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RIGOR; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UNSTEADINESS; VISUAL FIELD DEFECT;

ADOLESCENT; ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 79960188497     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.221     Document Type: Article

References (33)

1. Major EO, Amemiya K, Tornatore C, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5: 49-73.
2. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkins disease. Brain 1958; 81: 93-111.
3. Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, et al. for the Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy in 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48: 1459-1466.
4. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005; 17: 658-665. (Pubitemid 40558222)
5. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 2005; 353: 414-416. (Pubitemid 41132348)
6. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
7. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 2007; 39: 101-107. (Pubitemid 46085228)
8. Major EO. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 2009; 361: 1041-1043.
9. Kraemer C, Evers S, Nolting T, Arendt G, Husstedt IW. Cidofovir in combination with HAART and survival in AIDSassociated progressive multifocal leukoencephalopathy. J Neurol 2008; 255: 526-531.
10. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001; 75: 3483-3487. (Pubitemid 32225913)
11. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127: 1970-1978. (Pubitemid 39150256)
12. Khanna N, Wolbers M, Mueller NJ, Garzoni C, DuPasquier RA, Fux CA, et al. JCV-specific immune responses in HIV-1 patients with progressive multifocal leukoencephalopathy. J Virol 2009; 83: 4404-4411.
13. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
14. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-12.
15. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-1655. (Pubitemid 46776261)
16. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166. (Pubitemid 44527351)
17. Mader I, Herrlinger U, Klose U, Schmidt F, Kueker W. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion weighted MRI. Neuroradiology 2003; 45: 717-721. (Pubitemid 37376476)
18. Folstein MF, Folstein SE, McHugh PR. Mini Mental State a practical method for grading cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
19. Vago L, Cinque P, Sala E, Nebuloni M, Caldarelli R, Racca S, et al. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 139-146.
20. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9(Suppl 1): 88-92. (Pubitemid 36656477)
21. Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727-2735. (Pubitemid 350045762)
22. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, et al. Polyomavirus BK-specific cellular immune response to VP1 and Large T-antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131-1139. (Pubitemid 46643106)
23. Comoli P, Basso S, Azzi A, Moretta A, De Santis R, Del Galdo F, et al. Dendritic cells pulsed with polyomavirus BK antigen induce ex-vivo BKV-specific cytotoxic T cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 3197-3204. (Pubitemid 37509295)
24. Egli A, Infanti L, Dumoulin A, Buser A, Samarides J, Stebler C, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
25. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031-1036. (Pubitemid 40524670)
26. Heemskerk B, van Vreeswijk T, Veltrop-Duits LA, Sombroek CC, Franken K, Verhoosel RM, et al. Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction. J Immunol 2006; 177: 8851-8859. (Pubitemid 44893852)
27. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T-cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703. (Pubitemid 351860862)
28. Gasnault J, Kousignian P, Kahraman M, Rahoiljaon J, Matheron S, Delfraissy JF, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7: 375-381. (Pubitemid 32894245)
29. Focosi D, Kast RE, Maggi F, Lauria G, Ceccherini-Nelli L, Petrini M. 5-HT2a inhibitors for progressive multifocal leukoencephalopathy: old drugs for an old disease. J Infect Dis 2008; 197: 328-330.
30. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008; 111: 5342-5349.
31. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35: 1250-1257. (Pubitemid 35305874)
32. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361: 1075-1080.
33. Linda? H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081-1087.